Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
CH.1.1.28NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BF.5NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CH.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BF.7.6NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.5.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CH.1.1.19NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BM.4.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.5.2.35NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
KP.3.1.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
LF.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.16NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
KP.2.3.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
LQ.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
LY.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
MD.3.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
MK.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
LZ.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
MB.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BQ.1.10.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BQ.1.1.36NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
EF.1.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BQ.1.32NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
EK.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.2.6.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
DV.5NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FL.23.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.1.5.64NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.68NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.65 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.4.6.5NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.18NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.12.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
LZ.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
KP.3.1.5NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
KW.1.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
KU.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JN.1.4.6NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
KP.2.5NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
LP.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
KP.3.1.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
GQ.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JA.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
EG.5.1.10NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
FL.2.7.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
EG.9.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.2.3.22NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
JV.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.3.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CH.1.1.7NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.1.27NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used